Login to Your Account

Oryzon, Roche ink potential $500M deal on epigenetic modulator

By Cormac Sheridan
Staff Writer

Tuesday, April 8, 2014

Oryzon Genomics SA is getting $21 million in up-front and near-term milestones and could earn more than $500 million in total from a partnering deal with Roche AG on its lysine-specific demethylase-1 (LSD1) inhibitor program.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription